Primary-source record
The Phase 3 LOTIS-5 trial met its primary endpoint, demonstrating statistically significant PFS improvement for loncastuximab tesirine plus rituximab versus R-GemOx (HR 0.73, p=0.0083). This establishes the combination as a potential new standard in second-line or later r/r DLBCL and supports pursuit of regulatory pathways.
ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program News provided by ADC Therapeutics SA Nov 04, 2026, 09:00 ET Share this article Share this article ZYNLONTA data to be featured across 5 oral presentations and multiple posters Phase 1b LOTIS-7 abstract data demonstrates an 88.7% ORR and 75.3% CR with ZYNLONTA plus glofitamab across the 97 efficacy-evaluable r/r DLBCL patients Phase 2 marginal zone lymphoma IIT abstract shows robust and durable 93% ORR and 74.4% CRR with ZYNLONTA monotherapy Company to host conference call today at 4:15 p.m. EST LAUSANNE, Switzerland , Nov. 4, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT ), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced new and updated data from the ZYNLONTA® (loncastuximab tesirine-lpyl) clinical program will be shared across multiple abstracts, including five oral presentations, at the 68 th American Society of Hematology (ASH) Annual Meeting taking place December 12–15, 2026, in New Orleans, Louisiana. Across the presentations, the data provide additional insight into the depth and durability of response observed with ZYNLONTA across multiple B-cell lymphomas and treatment settings, including in difficult-to-treat patient populations. Oral presentations include e
ADC Therapeutics Announces Financial Restructuring and ASH 2026 Data Presentations for ZYNLONTA